D.E. Shaw & Co
TVRD

D.E. Shaw & Co’s Tvardi Therapeutics TVRD Stock Holding History

D.E. Shaw & Co’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,389
Closed -$1.09M – 5071
2021
Q1 		$1.09M Buy
+1,389
New +$951K ﹤0.01% 3049

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co's TVRD Position: Q2 2024 in Review

D.E. Shaw & Co sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 3,921 shares — an estimated $128K sold.

D.E. Shaw & Co first reported a position in TVRD in Q4 2014 and held it in 29 quarters. The position peaked at $6.57M in Q1 2020. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

  • D.E. Shaw & Co reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 3,921 Tvardi Therapeutics shares in Q2 2024, an estimated $128K.
  • D.E. Shaw & Co first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 29 quarters.
  • D.E. Shaw & Co's Tvardi Therapeutics position peaked at $6.57M in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.